We might, therefore, speculate that Aβ1–42 played a major role on cognitive impairment for PD patients at early stage, consistent with a recent study reporting that tau probably revealed the degree of neurodegeneration, whereas Aβ1–42 was a more specific marker for cognitive impairment. The gene discussed is MAPT; the disease is Cognitive impairment.